Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Bill Kelly

UConn alcohol research center continues run

Despite increasing competition for federal research dollars, the Alcohol Research Center at UConn Health endures well into its fifth decade with an unprecedented continuation of...

| By Bill Kelly

CT creates new workforce training entity

Connecticut lawmakers have seeded a newly created workforce fund with $1 million, and created a new board within the state’s Department of Labor to make grants...

| By Bill Kelly

UConn ranked top 10 for biological data research

According to CSRankings, an organization which compiles a metrics-based rankings of the top computer science programs in the world, the University of Connecticut ranks among...

| By Bill Kelly

Cybrexa closes $13.4m B1 funding round

Cybrexa Therapeutics has completed a $13.4 million Series B1 financing. “This level of financial support from our investors demonstrates the continued enthusiasm and validation for...

| By Bill Kelly

Shoreline Biome to Launch Product Suite

Shoreline Biome plans to unveil the market’s first end-to-end sample prep kit at the upcoming ASM Microbe 2019. The kit, Shoreline Complete, is an end-to-end...

| By Bill Kelly

Yale studies biology of hunger hormone leptin

In a new study, Yale researchers offer insight into leptin, a hormone that plays a key role in appetite, overeating, and obesity. Their findings advance...

| By Bill Kelly

FDA allows ReNetX Bio IND re spinal cord injury

ReNetX Bio reports that the FDA has has allowed the Company’s Investigational New Drug (IND) application for its lead drug candidate, fusion protein AXER-204. Axonal loss...

| By Bill Kelly

FDA accepts Melinta application re BAXDELA®

Melinta Therapeutics reports that the FDA has accepted a supplemental New Drug Application for BAXDELA® (delafloxacin) for priority review. The application seeks to expand the current indication for...

| By Bill Kelly

Alexion reports progress with ULTOMIRIS®

Alexion reports that the FDA  has accepted for priority review the company’s supplemental Biologics License Application (sBLA) for ULTOMIRIS® (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, for...

| By Bill Kelly

CT Pavilion shines at 2019 BIO Convention

The BIO International Convention, one of the world’s largest forums for the biotech sector, welcomed a record number of attendees to Philadelphia earlier this month. Connecticut was center...